Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Galena expands patent portfolio for GALE-401
January 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

PORTLAND, Ore.—Galena Biopharma Inc. announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for a patent application for GALE-401 composition of matter, a controlled-release formulation of anagrelide for use in reducing platelet counts in patients with myeloproliferative neoplasms. The claims encompass controlled-release formulations of GALE-401 in a broad range of unit dosage forms, articles of manufacture containing GALE-401 and methods of reducing platelet counts in patients with a variety of diseases by administering GALE-401, and the patent, when issued, expires in 2029.
 
“This composition of matter patent is an important component in the building of our patent family for GALE-401 … Our controlled-release version of anagrelide may offer treatment benefits for patients suffering from MPNs who may not be tolerating the currently available immediate-release version,” said Dr. Mark W. Schwartz, Galena's president and CEO.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.